3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Glioblastoma
3
Recurrence
2
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Melanoma
1
Lymphoma, T-Cell, Cutaneous
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Gliosarcoma
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
Paclitaxel
95
Carboplatin
76
pembrolizumab
72
Cisplatin
28
Bevacizumab
27
Letrozole
22
Radiotherapy
21
Doxorubicin
21
Megestrol Acetate
20
lenvatinib
19
olaparib
18
Taxes
17
Docetaxel
17
Nivolumab
16
Specimen Handling
15
Metformin
15
dostarlimab
14
Magnetic Resonance Spectroscopy
14
Gemcitabine
13
durvalumab
12
Medroxyprogesterone Acetate
12
Trastuzumab
11
Indocyanine Green
11
Fulvestrant
11
Biopsy
11
temsirolimus
10
abemaciclib
10
atezolizumab
9
Radiation
9
Early Intervention, Educational
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Endometrial Neoplasms
×
tinostamustine
×
Clear all
NCT03345485
2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2
Completed
71 enrolled
39 charts